BridgeBio Leadership Friday, June 26, 2026 0.00 Neutral

BridgeBio amends 2021 stock option and incentive plan

BridgeBio Pharma filed a Third Amended and Restated 2021 Stock Option and Incentive Plan. The update aims to expand equity compensation opportunities to align key personnel interests with shareholder value.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day